Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exagen Inc. - Common Stock (NQ: XGN )

6.210 +0.360 (+6.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,502
Open 5.870
Bid (Size) 5.300 (1)
Ask (Size) 6.690 (1)
Prev. Close 5.850
Today's Range 5.702 - 6.230
52wk Range 1.319 - 6.230
Shares Outstanding 16,126,784
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
From Exagen Inc.
Via GlobeNewswire

Performance

YTD
+100.97%
+100.97%
1 Month
+46.12%
+46.12%
3 Month
+55.25%
+55.25%
6 Month
+130.86%
+130.86%
1 Year
+340.43%
+340.43%

More News

Read More
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
From Exagen Inc.
Via GlobeNewswire
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Scheduled For March 11, 2025
Via Benzinga
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
Tuesday's session: top gainers and losers
Via Chartmill
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in Fourth Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. Reports Third Quarter 2024 Results
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Third Quarter 2024 Results on November 12, 2024
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
From Exagen Inc.
Via GlobeNewswire
Market Mayhem Winners: What Stocks Are Up Today?
Via InvestorPlace
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
From Exagen Inc.
Via GlobeNewswire
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
From Exagen Inc.
Via GlobeNewswire
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
From Exagen Inc.
Via GlobeNewswire
XGN Stock Earnings: Exagen Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
From Exagen Inc.
Via GlobeNewswire
Exagen Announces Campaign for Lupus Awareness Month
From Exagen Inc.
Via GlobeNewswire
Exagen to Announce First Quarter 2024 Results on May 13, 2024
From Exagen Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.